DISAB

Connect with us

National

AstraZeneca to run fresh COVID-19 vaccine trial amid results confusion – The Australian Financial Review

AstraZeneca and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.

Published

on

AstraZeneca and its partner, the University of Oxford, reported on Monday that a lower initial dose of the vaccine, followed by a full dose, produced a 90 per cent efficacy rate, compared with 62 per cent for two full doses.
A day after the data were unveiled the head of the US vaccine program known as Operation Warp Speed said that the regimen showing the higher level of effectiveness was tested in a younger population. He also said that the half-dose was given to some people because of an error…

Click here to view the original article.

Safety Mate